Abstract
This study investigated the expression of vascular endothelial growth factor (VEGF) and topoisomerase II alpha (TPII alpha) in a cohort of serous ovarian carcinomas by immunohistochemistry with regard to outcome and clinicopathologic variables. Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas and 41 serous ovarian carcinomas were immunostained with antibodies to VEGF and TPII alpha. Immunostaining for VEGF was scored with regard to quantity and intensity of positively stained cells as weak, focal strong, and diffuse strong. TPII alpha labeling indices (LI) were quantitated as the percentage of positively stained nuclei in 1000 tumor cells. VEGF expression was weak or negative in serous cystadenomas. In contrast, focal or diffuse strong immunostaining was observed in 21 cases (51%) of serous carcinomas. VEGF immunoreactivity was positively related with TPII alpha LI (P = 0.0055), adverse outcome (P = 0.0052), high International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.0158), and high tumor grade (P = 0.0303). TPII alpha LI increased with FIGO stage (P = 0.0076) as well as tumor grade (P = 0.0034) and indicated poor prognosis (P = 0.0182). VEGF immunoreactivity is rela...Continue Reading
References
Sep 1, 1993·Carcinogenesis·T Stevnsner, V A Bohr
Sep 1, 1996·Japanese Journal of Cancer Research : Gann·J MuT Hamaoka
May 7, 1998·Cancer Letters·E M HartenbachS Ramakrishnan
Jun 15, 1999·Gynecologic Oncology·G G GarzettiG Biagini
Jul 27, 1999·Gynecologic Oncology·C A ChenC Y Hsieh
Jul 25, 2000·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·M J CostaD Guinee
Dec 26, 2001·Gynecologic Oncology·Hermann Brustmann, Susanna Naudé
Nov 5, 2002·The American Journal of Pathology·Limin HuRobert B Jaffe
Apr 4, 2003·Cancer·Francis J GilesAlison T Stopeck
Jan 31, 2004·Gynecologic Oncology·Hermann Brustmann
Citations
Aug 27, 2013·Archives of Gynecology and Obstetrics·Umran Kucukgoz GulecAytekin Altintas
Mar 25, 2006·Journal of Clinical Pathology·C HughesJ O'Leary
Jul 29, 2010·Molecular Cancer Therapeutics·Seiji MabuchiTadashi Kimura
Jun 2, 2011·PloS One·Sameer MalhotraJonathan R Pollack
Feb 8, 2013·Diagnostic Pathology·Dinka SundovSnjezana Tomic
Jun 19, 2016·Journal of Ovarian Research·Yang BaiXin Lu
Jan 5, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivian GoodellMary L Disis
Jul 18, 2008·Supportive Cancer Therapy·Mutlu Dogan, Ahmet Demirkazik
Jan 1, 2010·Cancers·Cécile Le PageAnne-Marie Mes-Masson
May 29, 2008·British Journal of Cancer·G FerrandinaG Scambia
Jan 8, 2009·American Journal of Hematology·Chih-Cheng ChenChing-Fen Yang
Sep 23, 2009·Current Opinion in Obstetrics & Gynecology·Seiji MabuchiTadashi Kimura
Oct 14, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Kirsten M JochumsenOle Mogensen
Apr 21, 2012·Drugs·Sohita Dhillon
Aug 16, 2013·Oncology Letters·Limei WangShuhe Wang
Aug 11, 2018·Oncotarget·Bing-Qin Guo, Wen-Qiao Lu
Mar 1, 2011·Experimental and Therapeutic Medicine·Monica BinaschiCarlo Alberto Maggi
Jun 4, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sohita Dhillon
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seiji MabuchiMasahide Ohmichi
May 2, 2021·Biochemical Pharmacology·Chalita KingnateSiriporn C Chattipakorn